Prof Ashutosh Wechalekar speaks to ecancer about results from the phase 3 CARES trials evaluating anselamimab, a monoclonal antibody designed to promote clearance of amyloid fibrils, in patients with newly diagnosed AL amyloidosis receiving standard anti plasma cell therapy.

The study focuses on patients with advanced cardiac involvement and assesses whether adding anselamimab improves survival and cardiovascular outcomes.

In this trial, anselamimab demonstrated significant clinical benefit in the kappa light chain subgroup, with a 62 percent reduction in all cause mortality and a 71 percent reduction in cardiovascular hospitalizations compared with placebo. In contrast, patients with lambda light chain disease showed limited benefit, highlighting potential biological differences in treatment response.

Prof Wechalekar says that these findings support anselamimab as a promising targeted therapy for patients with kappa light chain AL amyloidosis, particularly those with advanced cardiac disease, and underscore the importance of stratifying treatment by light chain subtype.